2013

  1. Home
  2. 2013

Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder.

Balogh E, Madruga Dias J, Orr C, Mullan R, Harty L, FitzGerald O, Gallagher P, Molloy M, O’Flynn E, Kelly A, Minnock P, O’Neill M, Moore L, Murray M, Fearon U, Veale DJ. Arthritis Res Ther. 2013 Dec 24;15(6):R221.

Tumor necrosis factor inhibition modulates thrombospondin-1 expression in human inflammatory joint disease through altered NR4A2 activity.

McMorrow JP, Crean D, Gogarty M, Smyth A, Connolly M, Cummins E, Veale D, Fearon U, Tak PP, Fitzgerald O, Murphy EP. Am J Pathol. 2013 Oct;183(4):1243-57.

Notch signalling pathways mediate synovial angiogenesis in response to vascular endothelial growth factor and angiopoietin 2.

Gao W, Sweeney C, Walsh C, Rooney P, McCormick J, Veale DJ, Fearon U. Ann Rheum Dis. 2013 Jun;72(6):1080-8.

Is the serum amyloid A we use really serum amyloid A? Comment on the article by Connolly et al. Reply.

Mullan RH, Connolly M, Veale DJ, Fearon U. Arthritis Rheum. 2013 Jan;65(1):284-5.